[3-[[3-[2,3-Di(tetradecanoyloxy)propoxy-hydroxyphosphoryl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-tetradecanoyloxypropyl] tetradecanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: [3-[[3-[2,3-Di(tetradecanoyloxy)propoxy-hydroxyphosphoryl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-tetradecanoyloxypropyl] tetradecanoate
• 化学式: C₆₅H₁₂₆O₁₇P₂
• 分子量: 1241.6
• InChiKey: SDCJNZZAOLRVCP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  21.8
• 重原子数：
  84
• 可旋转键数：
  70
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  237
• 氢给体数：
  3
• 氢受体数：
  17

文献信息

• METHOD AND PROCESS FOR PREPARING CARDIOLIPIN
  申请人：Ali Shoukath M.

  公开号：US20100323000A1

  公开（公告）日：2010-12-23

  The invention provides novel methods for preparing cardiolipin and cardiolipin analogs having varying fatty acid chain lengths, particularly 1,1′,2,2′-tetramyristoyl cardiolipin. The methods comprise reacting a starting compound, such as a 1,2-O-sn-diacylglycerol and a 2-protected glycerol, with a phosphoramidite reagent to produce a protected cardiolipin, which is deprotected to prepare cardiolipin. The cardiolipin and cardiolipin analogs may be prepared in the presence of an activator, such as pyridinium trifluororacetate. The methods of the present invention are used to prepare cardiolipin and cardiolipin analogs in large quantities. The cardiolipin prepared by the present methods can be incorporated into liposomes which can also include active agents such as hydrophobic or hydrophilic drugs. Such liposomes can be used to treat diseases or in diagnostic and/or analytical assays.